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Prenatal Mechanistic Target of Rapamycin Complex 1 (m TORC1)
Inhibition by Rapamycin Treatment of Pregnant Mice Causes
Intrauterine Growth Restriction and Alters Postnatal Cardiac Growth,
Morphology, and Function
Maria Hennig, PhD; Saskia Fiedler; Christian Jux, MD; Ludwig Thierfelder, MD; J€org-Detlef Drenckhahn, MD
Background-—Fetal growth impacts cardiovascular health throughout postnatal life in humans. Various animal models of intrauterine
growth restriction exhibit reduced heart size at birth, which negatively influences cardiac function in adulthood. Themechanistic target
of rapamycin complex 1 (mTORC1) integrates nutrient and growth factor availability with cell growth, thereby regulating organ size.
This study aimed at elucidating a possible involvement of mTORC1 in intrauterine growth restriction and prenatal heart growth.
Methods and Results-—We inhibited mTORC1 in fetal mice by rapamycin treatment of pregnant dams in late gestation. Prenatal
rapamycin treatment reduces mTORC1 activity in various organs at birth, which is fully restored by postnatal day 3. Rapamycin-
treated neonates exhibit a 16% reduction in body weight compared with vehicle-treated controls. Heart weight decreases by 35%,
resulting in a significantly reduced heart weight/body weight ratio, smaller left ventricular dimensions, and reduced cardiac output in
rapamycin- versus vehicle-treated mice at birth. Although proliferation rates in neonatal rapamycin-treated hearts are unaffected,
cardiomyocyte size is reduced, and apoptosis increased compared with vehicle-treated neonates. Rapamycin-treated mice exhibit
postnatal catch-up growth, but body weight and left ventricular mass remain reduced in adulthood. Prenatal mTORC1 inhibition
causes a reduction in cardiomyocyte number in adult hearts compared with controls, which is partially compensated for by an
increased cardiomyocyte volume, resulting in normal cardiac function without maladaptive left ventricular remodeling.
Conclusions-—Prenatal rapamycin treatment of pregnant dams represents a new mouse model of intrauterine growth restriction
and identifies an important role of mTORC1 in perinatal cardiac growth. ( J Am Heart Assoc. 2017;6:e005506. DOI: 10.1161/
JAHA.117.005506.)
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T he intrauterine environment is a major determinant ofembryonic and fetal development. Various maternal or
environmental conditions can impair fetal growth, resulting in
intrauterine growth restriction (IUGR), which often presents
with low birth weight and reduced organ size.1 Maternal
under- or malnutrition, placental insufficiency, fetal hypoxia,
or drugs (eg, glucocorticoids) are among the factors causing
IUGR in humans and animal models.2 IUGR is considered a
major risk factor for various chronic diseases later in life and
thereby contributes to developmental (or fetal) programming.3
Hence, it appears imperative to uncover cellular and molec-
ular mechanisms that regulate intrauterine growth. Relatively
little is known about the underlying mechanisms, however,
but signaling pathways regulating cell growth and proliferation
are likely to be involved.
IUGR can be induced in animal models by caloric or protein
restriction in the maternal diet during pregnancy,2 which
suggests that a sufficient nutritional supply to the embryo and
fetus is required for normal intrauterine growth. The mecha-
nistic (or previously named “mammalian”) target of rapamycin
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(mTOR) pathway is an important sensor of the metabolic and
nutritional state of a cell and thereby integrates energy
homeostasis and amino acid availability with cell size and
proliferation.4 mTOR is a serine/threonine kinase present in 2
multiprotein complexes, mTORC1 and mTORC2, which differ in
the composition of regulatory and adaptor protein binding
partners. Whereas mTORC2 is best characterized for its
involvement in cell survival, growth, cytoskeletal organization,
and cell polarity, mTORC1 is a master regulator of cell growth
by activating protein, lipid, and nucleic acid biosynthesis while
inhibiting catabolic mechanisms such as autophagy.4 One of
the best characterized mTORC1 functions is the activation of
cap-dependent mRNA translation by phosphorylating its
downstream targets eukaryotic translation initiation factor 4E
binding protein 1 (4E-BP1) and ribosomal S6 kinase (S6K1). 4E-
BP1 phosphorylation results in its dissociation from eukaryotic
translation initiation factor 4E, thereby releasing its inhibitory
effect and allowing translation initiation. In addition, phospho-
rylation and activation of S6K1 and its downstream target S6
ribosomal protein favor mRNA biogenesis as well as translation
initiation and elongation. Upstream inputs that regulate
mTORC1 activity include cellular energy status (ie, glucose
and ATP levels), oxygen, growth factors, and amino acid
availability.4 Importantly, some (but not all) downstream
effects of mTORC1 (in contrast to mTORC2) can be efficiently
inhibited by the immunosuppressive drug rapamycin.
In various model organisms the mTOR pathway has been
shown to control organ size,5 which also includes the
mammalian heart. Although its role during postnatal physio-
logical as well as pathological cardiac hypertrophic growth
has been studied extensively,6 much less is known about the
involvement of mTOR signaling in prenatal cardiac develop-
ment. The heart conditional knockout of the gene encoding
mTOR in mice using Cre/loxP recombination mediated by
different cardiac Cre drivers has been shown to be lethal
during late gestation or at early postnatal stages.7-9 Efficient
inhibition of mTORC1 signaling in the heart, however, appears
to be either transiently restricted to a period shortly after
midgestation9 or is only achieved after birth,7,8 which
hampers final conclusions about its role in the fetal heart.
In addition, inactivating the mTOR gene affects both mTORC1
and mTORC2, such that precisely defining the role of one
versus the other is not feasible. Similarly, the heart
conditional knockout of the upstream mTORC1 activator
Ras homolog enriched in brain (Rheb) causes mTORC1
inhibition only after birth, subsequently leading to postnatal
lethality.10 Thus, the role of mTORC1 during embryonic and
fetal cardiac growth is incompletely understood.
Restricting amino acid availability in the maternal diet or
lowering ambient oxygen concentration during pregnancy as
well as reducing blood supply to the placenta cause IUGR in
animal models.1,2 Given that mTORC1 is inhibited by amino
acid starvation, hypoxia, and low cellular energy levels,
thereby impairing cell growth and proliferation,4 we hypoth-
esized that it might be involved in the IUGR phenotype. In
addition, most IUGR conditions reduce heart size at birth and
cause neonatal cardiac hypoplasia, which is considered a
major cardiovascular risk factor in adulthood.3 In this regard
we have recently described a mouse model of embryonic
heart regeneration based on inactivation of the X-linked gene
encoding holocytochrome c synthase (Hccs) specifically in the
developing heart.11 The HCCS enzyme is required for electron
transport along the mitochondrial respiratory chain. Heterozy-
gous heart conditional Hccs knock-out (KO) females (hereafter
referred to as cHccs+/) develop a tissue mosaic in the
ventricular myocardium composed of 50% cardiomyocytes
harboring mitochondrial dysfunction and 50% healthy cells at
midgestation. Compensatory proliferation of the healthy
cardiomyocyte population allows embryonic heart regenera-
tion, however, such that the neonatal cHccs+/ heart is
composed of 90% healthy cells and contains only 10%
diseased cells.11 Nevertheless, embryonic heart regeneration
is not sufficient to completely build up the myocardium,
resulting in cHccs+/ hearts being hypoplastic at birth due to
a reduced number of cardiomyocytes.12 This reduction in cell
number is postnatally compensated for by accelerated and
Clinical Perspective
What Is New?
• Pharmacological inhibition of the mechanistic target of
rapamycin complex 1 (mTORC1) pathway in late gestation
by rapamycin treatment of pregnant mice causes intrauter-
ine growth restriction, thereby reducing body and organ size
in the offspring at birth.
• Rapamycin-sensitive mTORC1 functions are required for
perinatal cardiac growth, primarily impacting cardiomyocyte
size and survival but not proliferation in the neonatal heart.
• Prenatal mTORC1 inhibition reduces cardiac output at birth
due to diminished left ventricular dimensions, but contrac-
tility is not affected.
• After prenatal mTORC1 inhibition body and heart weight
partially normalize until early adulthood, and cardiac output
fully recovers despite a reduced number of cardiomyocytes
in the adult heart.
What Are the Clinical Implications?
• Prenatal mTORC1 inhibition could play a role in intrauterine
growth restriction caused by various maternal or environ-
mental conditions, such as maternal mal- or undernutrition,
placental insufficiency, or fetal hypoxia.
• mTORC1 function is required for fetal cardiac growth, and
its inhibition might be involved in developmental program-
ming of heart disease in adulthood.
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augmented cardiomyocyte hypertrophic growth, such that
heart size normalizes by early adulthood.12 Given the
established role of mTORC1 in heart and organ size control,5,6
we speculated that mTORC1 activity might be important for
fetal cardiac growth and regulation of neonatal heart size in
general as well as for compensatory growth of cHccs+/
hearts in particular.
Here we show that inhibiting mTORC1 in the final quarter
of gestation by rapamycin treatment of pregnant mice causes
IUGR and reduces heart size and cardiac output at birth. Body
and heart size partially normalize during postnatal life, and
despite a reduction in cardiomyocyte number, cardiac func-
tion is not compromised in adult mice after prenatal mTORC1
inhibition. cHccs+/ mice after prenatal rapamycin treatment
exhibit cellular differences in the myocardium at birth
compared with controls but no major alterations of postnatal
heart size or function.
Methods
Mice
The generation and characterization of heart conditional Hccs
KO mice have been described previously.11 Briefly, floxed (fl)
Hccs mice were bred to mice expressing Cre recombinase
under the control of the Nkx2.5 promoter. All mice were
maintained on a mixed 129Sv/C57Bl6 genetic background,
and all experiments throughout the study were performed on
heterozygous Hccs KO females (Hccsfl/+/Nkx2.5Cre, referred
to as cHccs+/) and their respective Cre positive female
littermate controls (Hccs+/+/Nkx2.5Cre, referred to asHccs+/+).
The latter were furthermore used to compare the effects of
rapamycin versus vehicle treatment in control animals,
implying that all mice used in the study were carrying the
Nkx2.5Cre knock-in.13 Unless specifically annotated, all
results refer to control mice, whereas data of cHccs+/ mice
are explicitly labeled in figures or figure legends. The total
number of mice included in the different experiments of this
study is as follows: vehicle-treated neonates, Hccs+/+ n=31,
cHccs+/ n=30; rapamycin-treated neonates, Hccs+/+ n=39,
cHccs+/ n=41; vehicle-treated adults, Hccs+/+ n=9, cHccs+/
n=15; rapamycin-treated adults, Hccs+/+ n=9, cHccs+/
n=11. All animal procedures were performed following
institutional guidelines and had previously been approved by
the responsible authorities (Landesamt f€ur Gesundheit und
Soziales Berlin, approval number G 0027/10).
Rapamycin Injection
Female mice were mated to the respective males for 1 night
and separated the next morning (ie, at 0.5 days postconcep-
tion [dpc]). Dams with visible pregnancy at 14.5 dpc were
randomly assigned to vehicle or rapamycin treatment starting
in the morning at 15.5 dpc. Rapamycin (Cayman Chemical Co,
Ann Arbor, MI) was dissolved as stock solution (20 mg/mL) in
dimethylacetamide (DMA, Sigma-Aldrich, St. Louis, MO).
Pregnant dams were treated with rapamycin or vehicle by
subcutaneous injections every 12 hours from 15.5 dpc until
delivery. Each injection contained 5 mg rapamycin/kg body
weight diluted in 200 lL vehicle (10% PEG 300 [Sigma], 17%
Tween 80 [Sigma] in 0.9% NaCl solution) or DMA-containing
vehicle only. Injections were administered alternating into the
loose skin of the interscapular or the right and left femoral area.
Echocardiography
Adult mice (11 weeks old) were anesthetized by inhalation of
a 2.5% isoflurane/oxygen mixture using the Vevo compact
dual anesthesia system (VisualSonics, Toronto, ON, Canada).
Body temperature was kept constant at 37°C using a heat
lamp and a rectal temperature probe. Measurements on
neonates were performed on awake pups. Echocardiography
was recorded using the Vevo 2100 high-frequency ultrasound
system (VisualSonics, Toronto, ON, Canada) with a Micro-
ScanTM transducer MS400 set to 30 MHz for adult mice or
MS700 set to 50 MHz for neonatal mice. Operators were
blinded for mouse genotypes and treatment groups during
echocardiographic recordings as well as data analyses.
Organ Preparation and Histology
Hearts, kidneys, and lungs from neonatal mice were prepared
on postnatal day 1, and hearts, livers, kidneys, and spleens
from adult mice were prepared at the age of 11 weeks. Adult
mice were euthanized by cervical dislocation, and neonates
were decapitated. Organs were excised, rinsed in cold PBS,
weighed, snap-frozen in liquid nitrogen, and stored at 80°C.
If organs were used for histological analyses, they were fixed
in 4% paraformaldehyde/PBS (Sigma) for 24 to 48 hours. The
tissue was subsequently dehydrated through an increasing
ethanol series, cleared in toluol, and embedded in paraffin.
Five-micrometer paraffin sections were stained with hema-
toxylin and eosin (Carl Roth, Karlsruhe, Germany) to assess
overall cardiac morphology and tissue composition or with
Sirius Red (Direct Red 80, Sigma) to visualize myocardial
fibrosis.
Quantification of Fibrosis in Adult Hearts
Light microscopy images of Sirius Red–stained heart sections
from 11-week-old adult mice were taken using the Biozero BZ-
8100 microscope (Keyence, Osaka, Japan). Under 95 optical
magnification, 6 random fields of the left ventricular (LV)
myocardium, including free wall and interventricular septum,
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were imaged, thereby covering the entire LV tissue. Two
nonadjacent cross sections per heart were used. The
percentage of interstitial fibrotic tissue was quantified using
the color-threshold plugin of ImageJ software (https://imagej.
nih.gov/ij/), which measures the red-stained area in relation
to the total LV myocardial area. Values of all 12 images were
averaged to give the mean fibrotic tissue content for each
heart. Perivascular fibrosis was excluded and deleted from the
images before analysis.
Evaluation of Cell Proliferation
To assess proliferation rates in neonatal hearts, immunofluo-
rescence staining for Ki67 was performed. Paraffin sections
were deparaffinized and rehydrated, and heat-mediated antigen
retrieval was performed in sodium citrate buffer (10 mmol/L,
pH 6.0) for 20 minutes. After blocking in antibody solution
containing 5% normal goat serum (Jackson ImmunoResearch,
West Grove, PA) for 1 hour, sections were incubated overnight
with a rabbit monoclonal anti-Ki67 antibody (RM-9106, Thermo
Scientific, Waltham, MA) at 4°C. Secondary antibody detection
was performed at room temperature for 1 hour using a goat
anti-rabbit Alexa Fluor 555-conjugated secondary antibody
(Invitrogen, Carlsbad, CA). Nuclei were stained with 40,6-
diamidino-2-phenylindole (DAPI) (Invitrogen). Longitudinal sec-
tions were imaged with 940 optical magnification using the
Biozero BZ-8100 fluorescence microscope (Keyence, Osaka,
Japan), and 10 random fields per section were taken within the
LV myocardium, including the free wall and interventricular
septum. Cells that exhibited colocalization of Ki67 and DAPI
were considered to be cycling. Ki67-positive nuclei and the total
number of DAPI-stained nuclei were manually quantified using
the cell counter plugin of the ImageJ software. A total number of
5000 nuclei per heart were evaluated, and data from all 10
images were averaged to give the mean proliferation rate for
each heart.
Evaluation of Cell Death
Apoptotic cells were detected in cardiac paraffin sections
using a terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay (ApopTag Fluorescein Apoptosis
Detection Kit, Merck Millipore, Billerica, MA) according to the
manufacturer’s instructions. Nuclei were stained with DAPI
(Invitrogen). Two longitudinal nonadjacent TUNEL-stained
sections per heart and 6 random fields per section were
imaged using the Biozero BZ-8100 fluorescence microscope
(Keyence) with 915 optical magnification. Cells that exhibited
colocalization of TUNEL and DAPI staining were considered
apoptotic. TUNEL staining as well as the total number of DAPI-
stained nuclei were manually counted using ImageJ. A total
number of 15 000 nuclei per neonatal heart were analyzed,
and data from all 12 images were averaged to give the mean
apoptosis rate for each heart.
Cardiomyocyte Cross-Sectional Area, Length, and
Volume
To evaluate cardiomyocyte cross-sectional area (CSA), cardiac
paraffin sections were stained with fluorochrome-conjugated
wheat germ agglutinin (WGA, Alexa Fluor 555; Invitrogen) to
visualize cell membranes. Nuclei were stained with DAPI or
TO-PRO-3 (Invitrogen). For neonates, images were taken with
the confocal laser scanning microscope TSC SPE (Leica
Microsystems, Wetzlar, Germany) applying 9120 optical
magnification, whereas adult hearts were imaged with the
Biozero BZ-8100 fluorescence microscope (Keyence) applying
920 optical magnification. Fifteen random fields of the LV
myocardium including free wall and interventricular septum
were imaged per section, and 2 nonadjacent WGA-stained
sections per heart were used. At least 200 cardiomyocytes
per heart were measured using the area measurement tool of
the Biozero BZ image analysis application software (Keyence).
Only cardiomyocytes that were cut along their transverse axis
and matched the following selection criteria were included:
visible central nucleus, cell shape close to circular, clear cell
borders discernible, and visible cytoplasm. Values of all
cardiomyocytes were averaged to give a mean estimate of
cardiomyocyte CSA for each heart.
Cardiomyocyte length was measured in adult hearts
following immunofluorescence staining of paraffin sections
with WGA and an antibody against N-cadherin (sc-7939, Santa
Cruz Biotechnology, Dallas, TX) to identify intercalated disks
(general staining procedure same as for evaluation of
proliferation described above). Two nonadjacent sections
per heart were imaged at 940 magnification using a Zeiss
Axio Scope.A1 fluorescence microscope. Ten to 15 images
per section were taken from areas of the LV myocardium (free
wall and interventricular septum) that showed cardiomyocytes
in their longitudinal orientation. Rod-shaped cardiomyocytes
with clearly visible cell borders, nuclei and intercalated disks
were included. The distance between intercalated disks of
70 to 100 cardiomyocytes per heart was measured using
the ZEN blue software (Zeiss), and the average cardiomyocyte
length was calculated.
Calculation of cardiomyocyte volume was based on the
simplified assumption that cardiomyocytes are of cylindrical
shape (as previously described14), such that mean CSA was
multiplied by mean cardiomyocyte length for each adult heart.
Calculation of Cardiomyocyte Number Per Heart
Cardiomyocyte number per adult heart was estimated based
on previously published protocols15 with minor modifications.
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Heart volume was calculated by multiplying cardiac wet
weight or LV mass (determined by echocardiography) with the
tissue density of rat myocardium, ie, 1.048 g/mm3.15 The
relative contribution of cardiomyocytes to the cardiac tissue
was estimated by determining cardiomyocyte area fraction on
WGA-stained paraffin sections (staining as described above
for CSA). Briefly, LV myocardium of 2 nonadjacent sections
was imaged at 940 magnification, resulting in 20 to 30
images per heart. For each image the WGA-positive area
(including nonmyocytes, extracellular matrix, and cell mem-
branes) was measured using the color threshold plug-in in
ImageJ and related to the overall tissue area. The remaining
WGA-negative tissue area was considered to represent
cardiomyocytes. Cardiomyocyte area fraction was averaged
from all images per heart. Cardiomyocyte (CM) number was
calculated according to the following equation:
CM number ¼ heart volume CM area fraction
CM volume
Western Blot Analyses
For isolation of total protein extracts fresh or snap-frozen
tissue samples (heart, lung, kidney) were homogenized in
RIPA buffer supplemented with protease (Complete Protease
Inhibitor Cocktail Tablets, Roche Diagnostics, Indianapolis, IN)
and phosphatase inhibitors (PhosSTOP Phosphatase Inhibitor
Cocktail Tablets, Roche Diagnostics) and incubated at 4°C for
2 hours with gentle agitation. For samples on the same gel,
equal protein amounts were loaded (20 to 50 lg), separated
using denaturing SDS-PAGE and blotted onto nitrocellulose
(GE Healthcare, Chicago, IL) or polyvinylidene fluoride (Merck
Millipore) membranes. Membranes were blocked for 1 hour in
5% nonfat dry milk (Carl Roth) in Tris-buffered saline with
Tween 20 and incubated with the following primary antibodies
at 4°C overnight: phospho-S6K1 Thr389 (#9234), total S6K1
(#2708), phospho-S6 Ser235/236 (#4858), phospho-S6
Ser240/244 (#4838), total S6 (#2217), phospho-4E-BP1
Thr37/46 (#2855), phospho-4E-BP1 Ser65 (#9451), total 4E-
BP1 (#9644), phospho-mTOR Ser2448 (#2971), phospho-
mTOR Ser2481 (#2974), total mTOR (#2983), RICTOR
(#2114), RAPTOR (#2280), phospho-AMPKa Thr172
(#4188), total AMPKa (#2532), phospho-ULK1 Ser555
(#5869), phospho-ULK1 Ser757 (#6888), total ULK1
(#8054), LC3B (#3868), p62 (#5114), phospho-Akt Thr308
(#13038), phospho-Akt Ser473 (#4060), total Akt (#4691) (all
from Cell Signaling Technology, Danvers, MA). Antibodies
against GAPDH (MA1-22670, Thermo Scientific, Waltham,
MA), a-tubulin (T9026, Sigma-Aldrich, St. Louis, MO), and
vinculin (V9131, Sigma-Aldrich) were used for loading control.
Secondary detection was performed using horseradish per-
oxidase–linked secondary antibodies (Cell Signaling
Technology). Enhanced chemiluminescence reaction was
performed and detected with the imaging system Odyssey
Fc (LI-COR Biosciences, Lincoln, NE) or by exposure of the
membrane to chemiluminescence-sensitive CL-XPosure films
(Thermo Scientific). Intensity of detected protein bands was
quantified by densitometry using ImageJ.
Quantitative Real-Time Polymerase Chain
Reaction
Fresh or snap frozen cardiac tissue samples were homoge-
nized in TRIzol reagent (Invitrogen), and total RNA was
isolated according to the manufacturer’s instructions. RNA
was subsequently purified using RNeasy spin columns (Qia-
gen, Hilden, Germany), including digestion of genomic DNA on
the column (RNase-free DNase set, Qiagen). Isolated cardiac
RNA was reversely transcribed into cDNA using M-MuLV
reverse transcriptase (New England BioLabs, Ipswich, MA) and
random hexamer primers. Quantitative real-time polymerase
chain reaction (PCR) was performed using the Power SYBR
Green PCR Master Mix (Applied Biosystems, Foster City, CA)
on the ViiATM 7 real-time PCR system (Applied Biosystems).
Primers were obtained from BioTeZ (Berlin, Germany), and
sequences are as follows: Nppa forward 50-CAGCATGGGC
TCCTTCTCCAT-30, Nppa reverse 50- TGTACACAGGATTTGCTC-
CAATATG-30, Myh7 forward 50-CTAGAGTCAAAGTGGGCAACG-
30, Myh7 reverse 50-GTGTCACCATCCAGTTGAACA-30, Nppb
forward 50-AGGACCAAGGCCTCACAAAA-30, Nppb reverse 50-
TTGAGATATGTGTCACCTTGGAATTT-30. Target gene expression
was normalized against Gapdh: Gapdh forward 50-AGGTT
GTCTCCTGCGACTTCA-30, Gapdh reverse 50-CCAGGAAAT-
GAGCTTGACAAAGTT-30. All primers and PCR conditions were
optimized to PCR efficiencies between 90% and 110% and a
correlation coefficient ≥0.990 using cDNA dilution series. All
samples were analyzed in triplicate. Relative expression
differences between groups were determined using the DDCT
method.
Statistical Analyses
All data are presented as meanstandard error of the mean.
Data sets were tested for normal distribution by the
Kolmogorov-Smirnov test, and homogeneity of variances
between groups was assessed by the Levene test using SPSS
(IBM, Armonk, NY). If these criteria were met, differences
between 2 groups were evaluated with an unpaired, 2-sided
Student t test using Excel 2010 (Microsoft, Redmond, WA)
and those among multiple groups with 1-way ANOVA followed
by Bonferroni post hoc test using SPSS (IBM). Differences
among multiple groups with unequal variances were evaluated
with nonparametric Kruskal-Wallis 1-way analysis of variance
followed by Mann-Whitney post hoc test using SPSS (IBM).
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Genotype distributions were compared to expected Mendelian
distribution by a chi-squared test using Microsoft Excel.
Kaplan-Meier survival curves were plotted using SPSS, and
differences between groups were determined by a Log Rank
(Mantel-Cox) test. A probability (P) value less than 0.05 was
considered to indicate statistical significance.
Results
Efficient Inhibition of mTORC1 in Neonatal Mice
by Rapamycin Treatment of Pregnant Dams
In order to inhibit mTORC1 in fetal mice, we treated pregnant
dams during the final quarter of gestation (starting at
15.5 dpc until delivery) by subcutaneous injections of
rapamycin (5 mg/kg body weight) or vehicle every 12 hours
(Figure S1). mTORC1 activity was tested by Western blot
analyses on different tissues harvested from newborn mice on
postnatal day 1 (P1). Prenatal rapamycin treatment efficiently
reduced phosphorylation of the mTORC1 downstream targets
S6K1 and S6 ribosomal protein in the offspring heart, lung,
and kidney (Figure 1A). 4E-BP1 was unaffected, consistent
with previous reports showing different responsiveness of
mTORC1 targets to rapamycin.16,17
mTORC1 regulates autophagy in concert with AMP-
activated protein kinase (AMPK) by phosphorylating ULK1, a
kinase important for the initiation of autophagy.18 Phospho-
rylation of AMPKa was increased in rapamycin- compared
with vehicle-treated neonatal hearts (Figure S2A), as previ-
ously described in the mouse liver.19 Importantly, total ULK1
protein amounts are elevated in the P1 heart by prenatal
rapamycin treatment (Figure S2B). In agreement with AMPK
activation, ULK1 phosphorylation at the AMPK-dependent
residue Ser555 (which promotes autophagy) was increased in
rapamycin- compared with vehicle-treated hearts, even after
normalization to total ULK1 (Figure S2B). In contrast,
phosphorylation of the mTOR-sensitive Ser757, which inhibits
autophagy, was unaltered when normalized to total ULK1
(Figure S2B). In conclusion, besides opposing phosphorylation
by AMPK and mTOR, regulation of ULK1 activity in rapamycin-
treated neonatal hearts seems furthermore to involve altered
ULK1 protein stability and/or synthesis (as previously
proposed).20,21
To investigate the net effect of these interactions, we
tested protein levels of p62 (SQSTM1), which is rapidly
degraded if autophagy is activated,22 and found reduced p62
in hearts of rapamycin- compared with vehicle-treated
neonates (Figure 1B). In addition, we detected reduced
LC3B-I but unaltered LC3B-II protein amounts in rapamycin-
compared to vehicle-treated hearts (Figure 1B), a pattern also
observed in heart conditional Rheb KO mice.10 Consequently,
the LC3B-II/LC3B-I ratio is increased in rapamycin-treated
hearts, a parameter widely used to indicate activation of
autophagy. The fact that LC3B-II levels are not elevated, as
often reported, could indicate accelerated autophagic flux
such that, after conversion of LC3B-I to LC3B-II, the latter is
rapidly degraded via lysosomal turnover.22 Based on these
data we conclude that autophagy is activated in neonatal
hearts after prenatal rapamycin treatment.
It has been proposed that rapamycin can inhibit mTORC2 if
applied in high doses or for prolonged treatment periods.23,24
We did not detect differences in Akt phosphorylation at
Ser473 (Figure 1C), a well-established mTORC2 phosphoryla-
tion site, thereby excluding major inhibitory effects of
rapamycin on mTORC2 in the neonatal heart. Finally, given
that newborn pups did not receive further treatment after
birth, we wanted to know at what postnatal stage mTORC1
activity is fully restored. Western blot analyses revealed that
S6 phosphorylation in the heart is still reduced on postnatal
day 2 (P2) but returns to normal levels at P3 (Figure 1D). In
summary, rapamycin treatment of pregnant mice during late
gestation results in efficient inhibition of rapamycin-sensitive
mTORC1 functions in the offspring at birth, which in the heart
is restored by P3.
Prenatal Rapamycin Treatment Causes IUGR and
Reduces Heart Size at Birth
Prenatal rapamycin treatment in late gestation (starting at
15.5 dpc) does not cause fetal lethality, evident as
unaltered litter size in rapamycin- compared to vehicle-
treated dams on postnatal day 1 (Figure 2A). In contrast,
initiation of rapamycin treatment at 11.5 dpc resulted in
spontaneous abortions around 16.5 dpc and fetal lethality
with severe growth restriction and malformations. Conse-
quently, all further analyses were performed with treatment
commencing at 15.5 dpc (as depicted in Figure S1). Pups
born from rapamycin-treated females were smaller in size at
birth compared to vehicle-treated pups, resulting in a 16.4%
reduction in body weight (BW) (Figure 2B). Similarly, a
reduction in heart size was already evident upon dissection
and was furthermore confirmed by histological examination
(Figure 2C). The latter does not reveal any major structural
or morphological cardiac defects after prenatal mTORC1
inhibition, however. Strikingly, heart weight (HW) was
reduced by 34.5%, resulting in a significantly reduced
HW/BW ratio in rapamycin- versus vehicle-treated pups
(Figure 2D). In contrast, kidney weight (KW) was reduced in
accordance with BW by 19.7%, resulting in unaltered KW/
BW ratios between groups (Figure 2E). In conclusion,
rapamycin treatment during late gestation causes IUGR
evident as reduced body and organ size. Heart size is
disproportionately affected, suggesting that fetal cardiac
growth is specifically sensitive to mTORC1 inhibition.
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Prenatal Rapamycin Treatment Reduces
Cardiomyocyte Size and Induces Apoptosis
but Does Not Affect Proliferation in the
Neonatal Heart
The rapamycin-induced reduction in neonatal heart size
can be the result of different cellular mechanisms: a
reduction in cardiomyocyte size or number, and the
latter can be caused by induction of cell death or by
inhibition of proliferation. We determined cell cycle activ-
ity in neonatal (P1) hearts of rapamycin- compared to
vehicle-treated pups by Ki67 immunostaining but did not
find differences between the groups (Figure 3A). In con-
trast, when we assayed programmed cell death (apoptosis)
by TUNEL staining, a significant increase in the number of
TUNEL-positive cells was observed in rapamycin-treated
Figure 1. Efficient inhibition of mTORC1 in neonatal mice by rapamycin treatment of pregnant dams. A,
Western blots of protein extracts from neonatal (P1) heart, kidney, and lung tissue after prenatal vehicle or
rapamycin treatment. Reduced phosphorylation of the mTORC1 downstream targets S6K1 and S6
ribosomal protein confirmed successful mTORC1 inhibition by rapamycin in all 3 organs. In contrast,
phosphorylation of 4E-BP1 was unaffected in the neonatal heart. B, Western blots revealed reduced p62
(SQSTM1) and LC3B-I protein levels, resulting in an increased LC3B-II/LC3B-I ratio in hearts of rapamycin-
compared to vehicle-treated neonates (densitometric quantification n=6 per group for p62, n=4 for LC3B,
*P<0.05, **P<0.01). C, Western blots of Akt Ser473 phosphorylation normalized to total Akt revealed no
significant differences between hearts of rapamycin- and vehicle-treated neonates (densitometric
quantification n=5 per group). D, Western blots of heart protein extracts from vehicle-treated neonates
at P1 and rapamycin-treated littermates at P1, P2, and P3 illustrating phosphorylation status of S6
ribosomal protein. mTORC1 activity is still inhibited at P2 but restored by P3. B and C, Samples were
detected on the same membrane but were noncontiguous, indicated by a black line.
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Figure 2. Prenatal rapamycin treatment causes IUGR and reduces heart size at birth. A, Average litter size
of vehicle- and rapamycin-treated dams did not differ on postnatal day 1 (n=9 litters per treatment group). B,
Newborn offspring after prenatal rapamycin treatment were smaller compared to vehicle-treated controls
(scale bar=1 cm), resulting in significantly reduced body weight (BW). C, Neonatal mice after prenatal
rapamycin treatment had smaller hearts compared to their vehicle controls but did not exhibit major
structural or morphological cardiac defects (hematoxylin and eosin staining in lower panel, scale bars=1 mm;
Ao indicates aorta; IVS, interventricular septum; IUGR, intrauterine growth restriction; LA, left atrium; LV, left
ventricle; RA, right atrium; RV, right ventricle). D, Rapamycin-treated neonates demonstrated significantly
lower heart weight (HW) and HW/BW ratio compared to vehicle-treated animals. E, Even though kidney
weight (KW) of rapamycin-treated neonates was significantly reduced compared to vehicle-treated animals,
the KW/BW ratio was not altered. B, D, and E, Vehicle n=9, rapamycin n=10. (***P<0.001, *P<0.05).
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P1 hearts (Figure 3B). Most strikingly, cardiomyocyte
CSA was significantly reduced in the latter compared to
vehicle-treated pups, indicating a reduction in cell size
(Figure 3C). Taken together, these data suggest that
prenatal rapamycin treatment reduces cardiac organ size
primarily by reducing cardiomyocyte size in combination
with induction of apoptosis but not by interfering with
proliferation.
Figure 3. Prenatal rapamycin treatment reduces cardiomyocyte size and induces apoptosis but does not
affect proliferation in the postnatal day-1 heart. A, Quantification of immunofluorescence images of Ki67-
labeled nuclei (red) revealed unchanged proliferation rates within the left ventricular (LV) myocardium of
vehicle- and rapamycin-treated neonatal hearts. Nuclei were stained in blue with DAPI (scale bar=50 lm,
vehicle n=6, rapamycin n=12). B, Quantification of TUNEL-positive nuclei (green, see arrowheads) revealed
significantly increased apoptosis within the LV myocardium of neonatal hearts after prenatal mTORC1
inhibition compared to vehicle-treated controls. Nuclei were stained in blue with DAPI (scale bar=50 lm,
vehicle n=4, rapamycin n=6). C, Fluorescence staining of cardiomyocyte membranes with wheat germ
agglutinin (WGA, red) within the LV myocardium revealed a significantly reduced cardiomyocyte cross-
sectional area (CSA) in rapamycin- compared to vehicle-treated neonates. Nuclei were stained in blue with
TO-PRO-3 (confocal microscopy, scale bar=25 lm, vehicle n=5, rapamycin n=3). (***P<0.001, **P<0.01).
TUNEL indicates terminal deoxynucleotidyl transferase dUTP nick end labeling.
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Impact of Fetal mTORC1 Inhibition on a Mouse
Model of Prenatal Compensatory Cardiac Growth
Given the importance of mTOR for cardiac growth and organ
size control,5,6 it might be specifically required for embryonic
heart regeneration in cHccs+/ mice.11 Interestingly, neonatal
cHccs+/ hearts show increased phosphorylation of S6K1 and
S6 ribosomal protein (Figure 4A) but not of mTORC1 (ie, 4E-
BP1, ULK1) or mTORC2 (ie, Akt) (Figure S3) downstream
targets compared to controls. This suggests that perinatal
Figure 4. Impact of fetal mTORC1 inhibition on amousemodel of prenatal compensatory cardiac growth. A,
Western blots illustrating the phosphorylation status of S6K1 and S6 ribosomal protein revealed enhanced
mTORC1 activity in neonatal (P1) cHccs+/ hearts compared to littermate controls (densitometric
quantification for S6K1: Hccs+/+ n=15, cHccs+/ n=14, for S6: n=6 per group). B, Body weight (BW) of
rapamycin-treated neonates was significantly reduced compared to vehicle-treated animals, but no difference
was observed between genotypes. Rapamycin-treated Hccs+/+ and cHccs+/ neonates demonstrated similar
reductions in heart weight (HW) and HW/BW ratio compared to vehicle-treated animals. Note that the reduced
HW and HW/BW ratio in cHccs+/ compared to Hccs+/+ newborns reported previously12 persisted after
prenatal mTORC1 inhibition (vehicle groups n=9, rapamycin groups n=10). C, Quantification of Ki67-positive
nuclei revealed unchanged proliferation rates within the LV myocardium of vehicle- and rapamycin-treated
hearts and between genotypes (vehicle groups n=6, rapamycin Hccs+/+ n=12, rapamycin cHccs+/ n=13). D,
Quantification of TUNEL-positive nuclei revealed significantly increased apoptosis in hearts after prenatal
mTORC1 inhibition, with apoptosis in rapamycin-treated cHccs+/ hearts being significantly higher than in
rapamycin-treated Hccs+/+ controls (vehicle Hccs+/+ n=4, all other groups n=6). E, Prenatal rapamycin
treatment significantly reduced cardiomyocyte cross-sectional area (CSA) in both genotypes, and CSA in
rapamycin-treated cHccs+/ hearts was significantly smaller compared to rapamycin-treated Hccs+/+
controls (vehicle groups n=5, rapamycin groups n=3). B through E, Note that data used for Hccs+/+ animals
are the same as depicted in Figures 2 and 3, respectively. (*P<0.05, **P<0.01, ***P<0.001; §§§P<0.001 vs
vehicle Hccs+/+; ##P<0.01, ###P<0.001 vs vehicle cHccs+/). mTORC1 indicates mechanistic target of
rapamycin complex 1; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.
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compensatory cardiac growth, maturation, or cell survival in
cHccs+/ mice might depend on mTORC1 signaling to S6K1,
which has been shown to fulfill various functions in the heart.6
To address this question, we subjected cHccs+/ fetuses to
the same regime of prenatal rapamycin treatment as
described above (ie, starting at 15.5 dpc). Similarly to control
hearts, rapamycin efficiently inhibited mTORC1 activity in
cHccs+/ hearts on postnatal day P1 (Figure S4A). In litters
from rapamycin-treated dams, genotype distribution at P1
was as expected for X-chromosomal inheritance of Hccs and
not different from vehicle-treated litters (Figure S4B), exclud-
ing prenatal lethality of cHccs+/ females upon mTORC1
inhibition. Importantly, the rapamycin-induced reduction in
BW, HW, and HW/BW ratio was similar in cHccs+/ females
compared to rapamycin-treated controls (Hccs+/+) (Fig-
ure 4B). The reduction in heart weight in neonatal cHccs+/
compared to Hccs+/+ females due to the reduced number of
cardiomyocytes described previously12 was evident in both
treatment groups but was not aggravated by rapamycin. At
the cellular level, rapamycin does not specifically impair
proliferation in cHccs+/ hearts at P1 (Figure 4C) but further
induces apoptosis (Figure 4D) and reduces cardiomyocyte
CSA (Figure 4E) when compared to rapamycin-treated
Hccs+/+ females. In summary, whereas rapamycin does not
seem to affect late-gestational regulation of overall heart size
specifically in cHccs+/ females, it does have more pro-
nounced effects on cardiomyocyte size and cell survival. The
latter implies that rapamycin-sensitive mTORC1 functions
control certain cellular aspects of perinatal compensatory
growth and tissue homeostasis in cHccs+/ hearts, which
could impact on their morphology and function in adulthood
(see Discussion in Data S1).
Normal Contractility but Reduced Stroke Volume
and Cardiac Output in Neonatal Hearts After
Rapamycin Treatment
Considering the significant effects of prenatal mTORC1
inhibition on neonatal heart size, we performed echocardio-
graphy on rapamycin- and vehicle-treated pups at P1 in order
to evaluate cardiac function. In agreement with the heart
weight and morphology data described above, rapamycin-
treated neonates had a significantly reduced systolic LV wall
thickness (Figure 5A), a reduced LV internal diameter (Fig-
ure 5B), and a reduced calculated LV mass (Figure 5C). LV
contractility, however, was not affected by prenatal rapamycin
treatment (Figure 5D). The smaller LV dimensions result in a
significantly reduced LV stroke volume and cardiac output in
rapamycin- versus vehicle-treated pups, given that heart rate
was not different between groups (Figure 5E). In addition,
prenatal mTORC1 inhibition does not have more severe
effects on cardiac dimensions or function in cHccs+/
compared to Hccs+/+ females (Table S1). In summary,
prenatal rapamycin treatment reduces LV size and cardiac
output at birth.
Figure 5. Echocardiography revealed normal contractility but
reduced cardiac output in neonatal hearts after rapamycin
treatment. A, Interventricular septum (IVS) and left ventricular
posterior wall (LVPW) thickness in end-diastole (dia) and end-
systole (sys) were reduced after prenatal rapamycin treatment,
even though only systolic wall thickness reached statistical
significance. B, End-diastolic and end-systolic left ventricular
internal diameter (LVID) was reduced in neonatal mice after
prenatal mTORC1 inhibition, whereat only diastolic LVID was
significantly different. C, Neonatal LV mass calculated from
echocardiography data was significantly reduced after prenatal
rapamycin treatment. D, LV contractility at birth, measured as
fractional shortening (FS) and ejection fraction (EF), was not
affected by prenatal rapamycin treatment. E, The smaller LV
dimensions result in significantly reduced LV stroke volume and
consequently cardiac output in rapamycin- vs vehicle-treated
pups, given that heart rate was not different between groups. A
through E, Vehicle n=7, rapamycin n=6. *P<0.05, **P<0.01.
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Body and Organ Weights Partially Normalize After
Prenatal Rapamycin Treatment Until Adulthood
To monitor the postnatal fate of pups born after prenatal
mTORC1 inhibition, we analyzed rapamycin- and vehicle-
treated animals at the age of 11 weeks. As shown above,
mTORC1 activity is restored in the rapamycin-treated heart
3 days after birth (Figure 1D), suggesting that body and organ
growth should be uncompromised thereafter. Nevertheless,
we noticed postnatal lethality in a subset of rapamycin-
treated pups within the first 12 days after birth, resulting in
67.3% survival compared with 95.8% in vehicle-treated mice
(Figure 6A). After day 12 no further deaths were recorded,
and all animals survived to early adulthood. Comparison of
genotype distribution at weaning (ie, at 21 days of age)
revealed no evidence for preferential lethality of rapamycin-
treated cHccs+/ mice after birth (Figure S5). At the age of
11 weeks, rapamycin-treated animals still had a significantly
reduced BW and tibia length (TL) compared with vehicle-
treated mice (Figure 6B). BW was reduced by 10% compared
with 16% at birth, indicating a certain degree of postnatal
catch-up growth, however. Importantly, HW completely nor-
malizes in rapamycin- compared with vehicle-treated mice,
resulting in normal HW/BW and HW/TL ratios after 11 weeks
(Figure 6C). Histological examination confirmed mainly nor-
mal cardiac morphology, although hearts appeared slightly
smaller, and LV walls slightly thinner, compared with the
vehicle group (Figure 6D). Liver and spleen weights were not
different in adult rapamycin- versus vehicle-treated mice,
whereas KW was significantly reduced (Figure 6E). Neverthe-
less, organ weights normalized to BW or TL were not different
between treatment groups (Figure 6F and Table S2). More-
over, no specific effect of rapamycin treatment on body or
organ size was observed in cHccs+/ compared to Hccs+/+
females (Table S2). Taken together, after prenatal rapamycin
treatment, pups that survived the early postnatal period
showed incomplete catch-up growth of body and kidney size,
whereas heart, liver, and spleen weights all normalized until
adulthood.
Reduced LV Mass but Normal Cardiac
Contractility and Output in Adult Mice After
Prenatal Rapamycin Treatment
Long-term consequences of prenatal rapamycin treatment on
postnatal heart morphology and function were evaluated by
echocardiography at the age of 11 weeks. As suggested by
histological examinations (Figure 6D), rapamycin-treated ani-
mals had a significantly reduced LV wall thickness compared
with vehicle-treated controls (Figure 7A). The fact that LV
diameter was not different between the groups (Figure 7B)
resulted in a significantly reduced LV mass in rapamycin-
treated mice calculated from echo data, whereas the LV
mass/BW ratio was unaffected (Figure 7C). Similar to
neonatal stages, rapamycin-treated adults did not show
impairment of LV contractility (Figure 7D). Interestingly and
in contrast to newborns, LV stroke volume, heart rate, and
cardiac output were normal in rapamycin- compared with
vehicle-treated adults (Figure 7E). The latter suggests func-
tional recovery during postnatal life, considering reduced
cardiac output in rapamycin-treated animals at birth (Fig-
ure 5E). No major impairment of cardiac morphology and
function was observed in rapamycin-treated cHccs+/ com-
pared to Hccs+/+ females (Table S3), indicating that prenatal
mTORC1 inhibition does not negatively influence the long-
term outcome specifically in cHccs+/ females despite their
reliance on compensatory cardiac growth. In summary,
prenatal inhibition of rapamycin-sensitive mTORC1 functions
results in a sustained reduction of LV mass until early
adulthood. Despite unaltered overall cardiac wet weight
(Figure 6C), we conclude that LV dimensions are not
completely restored in rapamycin-treated mice within the
first 11 weeks of life, although heart size (ie, wet weight and
LV mass) appears largely appropriate when normalized to BW.
Reduced Cardiomyocyte Number but No
Maladaptive Remodeling in Adult Hearts After
Prenatal Rapamycin Treatment
The reduced LV wall thickness and mass in adult hearts after
prenatal rapamycin treatment could be caused by a reduction
in cardiomyocyte number or size. Surprisingly, cardiomyocyte
CSA was increased in rapamycin- compared with vehicle-
treated mice (Figure 8A), suggesting an increase in cell size. In
addition, we measured cardiomyocyte length in tissue sections
by N-cadherin immunofluorescence staining of the intercalated
disks between longitudinally oriented cells (Figure 8B). Car-
diomyocyte length was not different between rapamycin- and
vehicle-treated adult hearts (Figure 8B). Assuming a simplistic
model of cardiomyocytes being of cylindrical shape, multiplying
CSA by cell length allowed us to calculate the average
cardiomyocyte volume per heart. This revealed a significant
increase in cardiomyocyte volume in rapamycin- compared
with vehicle-treated adult hearts (Figure 8C). Considering
reduced LV mass in echocardiography and unchanged cardiac
wet weight in rapamycin-treated animals, the latter would
argue for compensatory cardiomyocyte hypertrophy to
account for a reduction in cell number. To estimate cardiomy-
ocyte number per heart, we first determined the relative
contribution of cardiomyocytes to the myocardium in WGA-
stained LV tissue sections. These data revealed a slightly but
significantly reduced cardiomyocyte area fraction in rapamy-
cin- compared with vehicle-treated adult hearts (Figure 8D).
Based on LV mass or cardiac wet weight, cardiomyocyte area
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fraction, and cardiomyocyte volume, we were able to calculate
the number of cardiomyocytes per heart (see Methods).
Although this allows only a rough assessment and likely
underestimates the absolute cardiomyocyte number, it should
be suitable for relative comparisons between treatment
groups. The results indeed revealed a significantly reduced
number of cardiomyocytes per heart in rapamycin- compared
with vehicle-treated mice in adulthood (Figure 8E). The reduc-
tion in cell number could be compensated for by excessive
deposition of extracellular matrix and therefore result in
maladaptive myocardial remodeling. We did not detect differ-
ences in interstitial fibrosis within the LV myocardium between
rapamycin- and vehicle-treated mice, however (Figure 8F).
Furthermore, RNA expression of fetal genes to indicate a
molecular signature of pathological conditions was not differ-
ent between groups (Figure 8G). Finally, prenatal rapamycin
treatment does not have more severe consequences on CSA,
fibrosis, or fetal gene expression in adult cHccs+/ compared
to Hccs+/+ females (Figure S6), indicating that prenatal
mTORC1 inhibition can be compensated in cHccs+/ hearts.
Taken together, prenatal rapamycin treatment reduces the
number of cardiomyocytes in the postnatal heart, which can be
partially compensated by increased cell volume to achieve a
near normal organ size.
Figure 6. Body and organ weights partially normalize after prenatal rapamycin treatment until adulthood. A, Survival curves show death of
some rapamycin-treated pups within the first 12 days after birth but not thereafter. Consequently, postnatal survival after 70 days is
significantly reduced in rapamycin- (n=55) vs vehicle-treated (n=48) animals (P<0.0005). Survival curves include all possible genotypes and both
sexes. B, Body weight (BW) and tibia length (TL) in 11-week-old adult mice after prenatal rapamycin treatment were reduced compared with
vehicle-treated animals, indicating incomplete postnatal catch-up growth. C, Heart weight (HW) in adult rapamycin-treated animals completely
normalizes during postnatal life, resulting in normal HW/BW and HW/TL ratios. D, Slightly reduced left ventricular (LV) wall thickness, but no
major morphological changes within the LV, interventricular septum (IVS) or right ventricle (RV), were observed after prenatal mTORC1 inhibition
compared to vehicle-treated animals (hematoxylin and eosin staining, scale bar=1 mm). E, Kidney weight (KW), but not liver (LW) or spleen
weight (SW), was significantly reduced in rapamycin- vs vehicle-treated 11-week-old mice. F, LW/BW, KW/BW and SW/BW ratios in adult mice
displayed no significant differences between the treatment groups. B, C, E, and F, Vehicle n=7, rapamycin n=9. (*P<0.05, **P<0.01). mTORC1
indicates mechanistic target of rapamycin complex 1.
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Intrauterine growth restriction can be induced by a variety of
maternal or environmental conditions, most of which converge
on the (single or combined) restriction of nutrients, energy, or
oxygen to the fetus.1 The cellular mechanisms that sense such
shortage and slow down intrauterine growth, however, are not
well understood. Here we show that rapamycin-sensitive
mTORC1 function regulates fetal growth and determines body
and organ size at birth. Given that mTORC1 integrates nutrient,
amino acid, and oxygen availability with cell growth and
proliferation,4 it seems likely that inhibition of mTORC1 by
different IUGR conditions is causally involved in fetal growth
restriction and aberrant organ maturation. Indeed, a low-
protein diet (LPD) fed to female mice throughout pregnancy
reduces pancreatic b-cell mass in the newborn offspring,
eventually leading to impaired insulin secretion and glucose
intolerance.25 LPD causes reduced mTORC1 activity in b-cells
at birth, and transiently restoring mTORC1 function rescues b-
cell mass and prevents the diabetic phenotype in the
offspring.25 In addition, food restriction in pregnant baboons
or sheep reduces mTORC1 activity in the fetal liver and
skeletal muscle, respectively.26,27 Although corresponding
data for the growth-restricted fetal or newborn heart are
missing, it is tempting to speculate that mTORC1 inhibition is a
general consequence of IUGR in various organs, thereby
contributing to developmental programming of adult disease.
Rapamycin treatment of pregnant dams represents a new
IUGR model in rodents, which could prove useful to study
developmental programming in various organ systems. We
have shown efficient inhibition of rapamycin-sensitive (ie,
S6K1, S6) but not rapamycin-insensitive (ie, 4E-BP1) mTORC1
downstream targets in the newborn heart, kidney, and liver
and a concomitant reduction in heart and kidney weight. For
animal studies of developmental programming, however, it
has been recommended to use only 1 representative male
and/or female offspring per litter in order to account for
differences in the intrauterine or postnatal environment
specific for certain pregnancies or dams. A limitation of
the current study in this regard is that we included several
Hccs+/+ and cHccs+/ females from the same litter, which is
common practice when analyzing genetically modified mice.
Consequently, we cannot exclude that the close relationship
of littermates in contrast to randomly chosen mice might have
an effect on certain study results. The rapamycin treatment
protocol applied in this study (ie, starting at 15.5 dpc) results
in a quite stable 16% reduction in neonatal body weight, the
degree of which is comparable to other IUGR studies.28-30 In
contrast, the widely used maternal protein restriction during
pregnancy has shown quite remarkable variations in neonatal
body weight between different studies and investigators,
which are likely to be influenced by the mouse or rat strain
used, the exact diet composition, the precise onset of LPD,
the duration of LPD after birth, and other variables (reviewed
by Zohdi et al31). In this regard we believe that rapamycin
treatment of pregnant dams is easy to control and can be
standardized to achieve consistent degrees of growth
Figure 7. Echocardiography revealed reduced left ventricular
(LV) mass but normal cardiac function in adult mice after prenatal
rapamycin treatment. A, Interventricular septum (IVS) and left
ventricular posterior wall (LVPW) thickness in end-diastole (dia)
and end-systole (sys) were reduced in adult hearts after prenatal
rapamycin compared with vehicle treatment, even though systolic
LVPW missed statistical significance. B, End-diastolic and end-
systolic left ventricular internal diameter (LVID) was not different
between the groups. C, LV mass calculated from echocardiogra-
phy data was significantly reduced in adult mice after prenatal
mTORC1 inhibition compared with vehicle-treated animals,
whereas the LV mass/BW ratio was unaffected. D, Rapamycin-
treated adults did not show impairment of LV contractility, as
indicated by normal fractional shortening (FS). E, LV stroke
volume, heart rate, and cardiac output were normal in rapamycin-
compared with vehicle-treated adults. A through E, Vehicle n=7,
rapamycin n=9. (*P<0.05, **P<0.01). mTORC1 indicates
mechanistic target of rapamycin complex 1.
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restriction and therefore reproducible results when studying
fetal programming in adulthood. Furthermore, the rapamycin
dose can potentially be adjusted to regulate the degree of
IUGR, and an adapted treatment regime might even allow to
precisely time the period of mTORC1 inhibition by starting and
terminating rapamycin application at the desired gestational
stage. Such a protocol could determine time windows during
embryonic or fetal development that are most susceptible to
growth restriction and therefore most relevant for develop-
mental programming.
An important consideration in assessing the new IUGR
model described here is the effect of rapamycin on the
maternal organism. Because it is applied systemically to
pregnant mice, it is likely to interfere with placental growth
and function, even though placental development is already
well established at the onset of treatment (ie, 15.5 dpc in this
study).32 Nevertheless, mTORC1 signaling has been shown to
play an important role in placental nutrient sensing and
consequently maternal-to-fetal nutrient exchange.33 Interest-
ingly, however, mTORC1 activity is reduced in the placenta by
maternal protein or nutrient restriction in rats and baboons,
respectively,28,29 as well as in human placentas upon
IUGR.34,35 Systemic rapamycin administration to pregnant
dams could furthermore interfere with mammary gland
development, thereby impairing lactation and milk intake of
newborn offspring. Indeed, treatment of pregnant mice with
the mTORC1 inhibitor RAD001 or rapamycin starting on the
day before delivery and continuing for 5 or 12 days,
respectively, disturbs mammary gland tissue architecture
and reduces organ size, milk protein production, and pup
Figure 8. Cardiomyocyte number is reduced, but cell volume is increased in adult hearts after prenatal rapamycin treatment. A,
Cardiomyocyte cross-sectional area (CSA) was significantly larger in adult hearts exposed to prenatal rapamycin treatment compared with
vehicle (vehicle n=6, rapamycin n=7). B, Immunofluorescence staining for N-cadherin to visualize intercalated disks (red), WGA to detect cell
membranes (green), and DAPI to stain nuclei (blue) in adult hearts. White lines indicate representative longitudinally oriented cardiomyocytes
used to measure the distance between 2 intercalated disks (scale bar=50 lm). Cardiomyocyte length was not different between vehicle- and
rapamycin-treated adult hearts. C, Calculated cardiomyocyte volume is significantly increased in adult hearts after prenatal rapamycin vs vehicle
treatment. D, Cardiomyocyte area fraction is slightly but significantly lower in rapamycin- vs vehicle-treated adult hearts. E, Calculation of
cardiomyocyte number revealed a significant reduction in adult hearts after prenatal rapamycin treatment compared with vehicle controls (n=5
per group in B through E). F, Quantification of interstitial fibrosis within the left ventricle myocardium of adult mice did not reveal differences
between the treatment groups (vehicle n=6, rapamycin n=8). G, RNA expression of Nppa (natriuretic peptide type A), Myh7 (b-myosin heavy
chain 7) and Nppb (natriuretic peptide type B) was determined in adult hearts by quantitative real-time polymerase chain reaction. For all 3
genes no significant difference was observed after prenatal rapamycin compared to vehicle treatment (n=8 per group). (*P<0.05, **P<0.01).
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weight.36,37 Rapamycin furthermore reduces milk protein
production in murine and bovine mammary epithelial cells
in vitro, which was also observed upon amino acid starva-
tion.38 Importantly, maternal LPD during pregnancy in rats
impairs late gestation mammary gland development,39 and
uteroplacental insufficiency induced by uterine artery ligation
in rats impairs mammary gland development and function as
well as milk production and composition, thereby restraining
postnatal pup growth.30 These studies indicate that impaired
mammary gland function as well as placental mTORC1
inhibition appear to be general features of various IUGR
animal models, such that a potential maternal impact by
rapamycin treatment would not be fundamentally different.
The degree of the latter will have to be compared to other
IUGR models in future studies, however. This appears
furthermore warranted considering lethality in 30% of
rapamycin-treated pups during the first 12 postnatal days
(Figure 6A).The latter could well be caused by lactation
insufficiency or metabolic alterations in the maternal organ-
ism, resulting in undernourishment of the offspring. Alterna-
tively, postnatal lethality could be independent of maternal
factors and might be the result of variable severity of
rapamycin-induced IUGR and organ dysfunction or impaired
postnatal compensatory processes (eg, insufficient catch-up
growth) in some pups.
Our data show that full mTORC1 activity is essential for
fetal heart growth during late gestation, given that neonates
after prenatal rapamycin treatment have small hearts and a
reduced HW/BW ratio compared with vehicle-treated con-
trols. The latter is the result of a disproportional (34.5%)
reduction in HW compared with BW (16.4%). These findings
are in contrast to maternal LPD or placental insufficiency in
rats, in which reduction in offspring HW parallels the reduction
in BW, such that HW/BW ratio is normal.30,31 Interestingly,
the reduction in KW (19.7%) in rapamycin-treated pups was
proportional to body weight, resulting in normal KW/BW
ratios. These data suggest that fetal heart growth more
heavily depends on rapamycin-sensitive mTORC1 activity as
compared with other organs and that the prenatal heart might
be specifically susceptible to fetal programming involving
mTORC1 inhibition.
Decreased neonatal heart size after prenatal rapamycin
treatment is primarily caused by a reduction in cardiomyocyte
size, whereas proliferation is unaffected at birth. This is in
agreement with rapamycin inhibiting phosphorylation of S6K1
but not 4E-BP1 in the neonatal heart, as it has been shown
that 4E-BP1 primarily mediates the proliferative effects
downstream of mTORC1, whereas S6K1 regulates cell
size.40,41 It is furthermore consistent with the heart condi-
tional knockout of mTOR and the upstream mTORC1 activator
Rheb, both of which result in full mTORC1 inhibition shortly
after birth with reduced cardiomyocyte size by days 8 and 15,
respectively,7,10 whereas proliferation rates were not directly
determined. We furthermore detected increased apoptotic
cell death within the myocardium of rapamycin-treated
neonates, which is in agreement with previous studies
showing cardiomyocyte apoptosis upon mTORC1 inhibition
in the embryonic or early postnatal heart.7-9 It is tempting to
speculate that in addition to diminished cell size a reduced
cardiomyocyte number due to rapamycin-induced cell death
might also contribute to the reduction in heart size. A
limitation of our study, however, is that we did not differen-
tiate between cell types when determining proliferation and
apoptosis, so we cannot exclude that primarily a nonmyocyte
cell population is undergoing cell death. Similarly, unaltered
overall proliferation rates in the myocardium could obscure
slight differences between cardiac cell types. Nevertheless,
when studying adult hearts after prenatal rapamycin treat-
ment, morphometric calculations revealed a reduced car-
diomyocyte number in rapamycin- versus vehicle-treated
hearts in adulthood. An intriguing question is whether this
cardiomyocyte deficit is solely due to increased cardiomy-
ocyte apoptosis in the perinatal phase or whether impaired
proliferation in the prenatal period also contributes. In
addition, given that murine cardiomyocytes can proliferate
during the first postnatal week,42 and mTORC1 activity is only
restored by day 3, cardiomyocyte proliferation could also be
impaired shortly after birth. A limitation of our study in this
regard is that we did not investigate fetal hearts or placental
morphology and function between commencement of rapa-
mycin treatment at 15.5 dpc and birth. Therefore, we cannot
exclude that rapamycin induces metabolic alterations in the
mother or molecular changes in the placenta that generally
impair nutrient supply to the fetus, thereby potentially
inhibiting fetal (cardiac) growth beyond the rapamycin-
sensitive functions of mTORC1. For example, impaired
placental amino acid exchange28,29,34 could potentially result
in full mTOR inhibition, which in turn could inhibit cardiomy-
ocyte proliferation in the fetus. Given that such rapamycin-
independent inhibitory effects would be restored quickly after
birth, our current study might be unable to detect the
molecular and cellular consequences when investigating
hearts on postnatal day 1. So whether rapamycin-treated
neonates are born with a reduced cardiomyocyte number or
whether this develops after birth will have to be determined in
future studies, in parallel with investigations of placental
function.
The reduction in body and organ weight in rapamycin-
treated mice at birth is partially normalized until early
adulthood. Body weight and tibia length remain slightly
reduced at the age of 11 weeks, which is in agreement with
persistent weight reduction in other IUGR rodent models.31,43
Interestingly, the ability for postnatal catch-up growth appears
to vary among organs. Although absolute heart, liver, and
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spleen weights are mainly normal in 11-week-old rapamycin-
compared with vehicle-treated animals, kidney weight is still
reduced, although not different when normalized to body
weight or tibia length. Nevertheless, these data suggest that
the kidney has an impaired postnatal growth plasticity in
response to IUGR (as previously proposed by human as well
as animal studies43,44), which might contribute to develop-
mental programming of hypertension and kidney disease. For
the heart, we observed a discrepancy between overall
gravimetric wet weight and LV mass calculated from
echocardiography data. Whereas the latter was reduced in
rapamycin- versus vehicle-treated mice in adulthood, wet
weight was unchanged. These differences are likely caused by
the impact of blood or fluids in the cardiac cavities as well as
right ventricular and atrial myocardium on wet weight but not
LV mass calculations. Given that histological examinations
and echocardiography data confirmed slightly reduced LV wall
thickness in rapamycin- versus vehicle-treated adult mice, we
conclude that heart dimensions are not fully normalized until
early adulthood after prenatal mTORC1 inhibition. This is in
contrast to other IUGR animal models, which mainly revealed
unaltered heart size in adulthood, although it was often
determined as wet weight at later stages.31,43 Therefore, it is
quite possible that LV mass completely normalizes in
rapamycin-treated mice with further aging.
Neonates after prenatal rapamycin treatment show
reduced cardiac output caused by smaller LV dimensions
and stroke volume but not impaired contractility when
compared with vehicle-treated controls. This is in contrast
to mice with an inducible, heart conditional knockout of
mTOR or Raptor in adulthood, which develop contractile
dysfunction and heart failure under baseline conditions,45,46
although over a period of 4 to 6 weeks. Importantly, it is
also different from heart conditional Rheb KO mice, which
show efficient mTORC1 inhibition by postnatal day 5 and
contractile dysfunction by day 8.10 Similarly, heart condi-
tional mTOR KO mice that exhibit efficient mTOR protein
depletion by postnatal day 7 develop contractile dysfunction
by day 15.7 The latter 2 genetic models, however, cause a
broad inhibition of mTORC1 (and also mTORC2 in case of
the mTOR knockout) in the heart beyond rapamycin-
sensitive functions, evident as decreased phosphorylation
of 4E-BP1, which was unaffected in our current study. These
data suggest that LV contractility in fetal and neonatal
hearts is relatively insensitive toward rapamycin-dependent
mTORC1 inhibition, and cardiac output is primarily deter-
mined by LV volume. Within the first few weeks after birth,
however, mTORC1 activity becomes essential to establish
and maintain normal LV function. The latter coincides with
various milestones of postnatal cardiac maturation, such as
changes in cardiomyocyte metabolism, growth pattern,
tissue composition, and myocardial workload.47 Thus, it is
tempting to speculate that mTORC1 plays an important role
in the transition from fetal to postnatal cardiac growth and
function.
Despite slightly reduced LV mass and wall thickness and a
reduced number of cardiomyocytes, adult hearts after prena-
tal rapamycin treatment exhibit normal contractility and
complete recovery of cardiac output as compared with
neonatal stages without signs of maladaptive myocardial
remodeling. This is consistent with some rodent studies
showing unaltered LV contractility after IUGR under baseline
conditions in adulthood,31,48 but others have reported
reduced heart function at 10 to 12 weeks of age.49,50
Similarly, most IUGR animal models eventually show
increased myocardial fibrosis with age, whereas the onset
of tissue remodeling in early adulthood is less clear.31,49,51 In
addition, maternal LPD during pregnancy has recently been
proposed to alter the biochemical composition of myocardial
tissue in adult offspring.51 Whether this represents a general
effect of IUGR or whether it is specific to the LPD model
needs to be confirmed, such that characterizing the cardiac
lipid, proteoglycan, and carbohydrate profile in rapamycin-
treated hearts might add valuable information to this ques-
tion. So although prenatal rapamycin treatment obviously
results in an IUGR phenotype at birth, it will have to be
established whether it furthermore represents a suitable
model for fetal programming in adulthood. In this regard it will
be interesting to determine the long-term cardiac outcome of
adult mice after prenatal rapamycin treatment upon aging as
well as their response to various challenges (such as
ischemia, pressure overload, or neurohumoral stimulation) in
future studies. Such data would have important implications
for both fetal programming in general as well as for the
specific role of mTORC1 in long-term cardiovascular health
and disease susceptibility.
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Data S1. Supplemental Discussion 
To evaluate a role of mTORC1 in compensatory fetal cardiac growth we investigated the 
effect of prenatal rapamycin treatment on cHccs+/- mice. The latter develop a tissue mosaic 
of healthy and defective cells in the ventricular myocardium at mid-gestation, but 
compensatory hyperproliferation of healthy cells allows formation of a fully functional 
heart primarily composed of healthy cardiomyocytes at birth.1 Nevertheless, embryonic 
heart regeneration is insufficient to completely build up the heart, such that neonatal 
cHccs+/- mice exhibit reduced heart size at birth due to a reduced number of 
cardiomyocytes.2 The latter is postnatally compensated for by accelerated 
physiological hypertrophy, resulting in normalization of organ size by early adulthood.2 
Here we show increased phosphorylation of the mTORC1 downstream targets S6K1 and S6 
ribosomal protein in neonatal cHccs+/- hearts compared to littermate controls (Figure 4), 
suggesting a role of mTORC1 in pre- or postnatal compensatory growth and adaptation. 
Surprisingly, prenatal rapamycin treatment causes only marginal differences in cHccs+/- 
compared to Hccs+/+ newborn hearts. mTORC1 does not seem to be specifically required 
for establishing the size of cHccs+/- hearts by birth, given that the reduction in heart weight 
in rapamycin compared to vehicle treated animals is similar to Hccs+/+ mice (34.5% versus 
35.3%). Also, the previously reported reduction in heart weight and HW/BW ratio in cHccs+/- 
compared to Hccs+/+ hearts at birth 2 was evident in vehicle and rapamycin treated animals 
but not further aggravated by rapamycin. Prenatal rapamycin treatment does not 
specifically impair proliferation in neonatal cHccs+/- hearts.  Of note, compensatory 
proliferation in cHccs+/- hearts is no longer evident at P1, as reported previously 2 
and observed in vehicle treated cHccs+/- compared to Hccs+/+ neonates. A limitation of 
our studies in this regard is that we did not determine proliferation specifically in healthy 
versus HCCS deficient cardiomyocytes or non-myocytes. Therefore, slightly different 
proliferation rates in one cell population versus the other, which might be differentially 
affected by rapamycin in cHccs+/- compared to Hccs+/+ neonates, would be missed. 
Nevertheless, hyperproliferation of healthy cardiomyocytes in cHccs+/- hearts was mainly 
observed during embryonic stages (i.e. at 11.5 and 13.5 dpc).1 Consequently, the rapamycin 
treatment protocol applied in the current study (i.e. starting at 15.5 dpc) misses the 
main window of compensatory proliferation. Commencement of rapamycin treatment at 
11.5 dpc, however, resulted in spontaneous abortions and fetal death, thereby impeding 
attempts to study the role of mTORC1 in the main regenerative phase. Proliferation 
during the fetal period was not investigated in our previous 1 or the current study, such that 
a potential effect of rapamycin treatment on compensatory proliferation of healthy 
cardiomyocytes in the fetal cHccs+/- heart cannot be excluded. Such scenario seems 
unlikely, however, given that the reduction in heart weight and HW/BW ratio in cHccs+/- 
compared to Hccs+/+ neonates is not aggravated by rapamycin. In summary, future 
studies using adapted rapamycin treatment protocols or genetic models resulting in heart 
specific inhibition of mTORC1 might help to unravel its precise role in embryonic heart 
regeneration. 
Whereas apoptosis rates in the neonatal heart are not different in cHccs+/- compared to 
Hccs+/+ mice under baseline conditions (see 2 and vehicle groups in the current study), 
prenatal rapamycin treatment induces cell death in both genotypes when compared to 
vehicle and apoptosis is even further increased in rapamycin treated cHccs+/-
 hearts. It is tempting to speculate that the latter might be caused by death of the ~10% of 
HCCS deficient cardiomyocytes that remain in the neonatal cHccs+/- heart.1 Although we did 
not differentiate between cell types (i.e. cardiomyocytes versus non-myocytes or 
healthy versus HCCS deficient cardiomyocytes) when performing TUNEL staining, 
immunofluorescence staining for cleaved caspase 3 did not reveal increased apoptosis of 
HCCS deficient cardiomyocytes upon rapamycin treatment (data not shown). Thus, the 
primary cell type undergoing cell 
death in the neonatal Hccs+/+ as well as cHccs+/- heart upon mTORC1 inhibition will have 
to be determined in future studies. 
Prenatal rapamycin treatment more severely disturbs fetal cardiomyocyte growth in cHccs
+/- versus Hccs+/+ mice compared to their respective vehicle group. Whereas 
cardiomyocyte cross sectional area is not different between genotypes under baseline 
conditions (see 2 and vehicle treated animals), rapamycin causes a significant reduction in 
cHccs+/- compared to Hccs+/+ mice. These data suggest that establishing a normal 
cardiomyocyte size in the neonatal cHccs+/- heart depends on mTORC1. In contrast, 
hyperactivation of mTORC1 is unable to raise cell size above the level of control mice 
to compensate for the reduced cardiomyocyte number and normalize organ size at 
birth. This suggests that plasticity of cardiomyocyte size in the perinatal heart is limited 
and compensatory hypertrophic growth primarily occurs during postnatal development, 
as observed in cHccs+/- mice.2 Another possible explanation is that further increasing 
cardiomyocyte size might shift physiological hypertrophy towards pathological cardiac 
growth and maladaptive remodeling. Therefore, cardiomyocyte size appears to be 
tightly controlled in the neonatal heart even under conditions of reduced cell number, 
and mTORC1 activity might be restricted to prevent unrestrained cardiac growth. An 
important question in this regard is, why the reduced CSA in cHccs+/- compared to Hccs+/+ 
neonates upon rapamycin treatment does not translate into a more pronounced reduction 
in cHccs+/- heart size. The latter could be due to compensation by increased extracellular 
matrix deposition (i.e. fibrosis). Although we did not measure fibrosis in the neonatal 
heart, we did not detect differences between rapamycin and vehicle treated mice or 
between genotypes in adulthood, making a transient fibrotic compensation in rapamycin 
treated cHccs+/- hearts around birth rather unlikely. In addition, myocardial 
replacement fibrosis is rarely observed in newborn mice and the neonatal murine heart 
can fully regenerate after apex resection or myocardial infarction without formation 
of a permanent fibrotic scar.3 Another possible explanation for maintained heart
size in rapamycin treated cHccs+/- relative to Hccs+/+ neonates despite reduced 
cardiomyocyte size would be compensation by a non-myocyte cell population. In this regard, 
adult Hccs+/+ hearts show a slightly reduced cardiomyocyte area fraction after prenatal 
rapamycin compared to vehicle treatment. In the absence of myocardial fibrosis (as 
demonstrated in Figure S6), this might indicate an increased abundance of a non-myocyte 
cell population. Whether changes in cardiomyocyte area fraction in rapamycin treated hearts 
are already detectable at birth and more pronounced in cHccs+/- neonates is uncertain, 
however. In summary, future studies will have to investigate possible changes in 
myocardial tissue composition after prenatal rapamycin treatment at birth and in 
adulthood. 
Finally, prenatal rapamycin treatment does not cause any long-term negative effects 
on cardiac organ size, morphology or LV function in adult cHccs+/- compared to Hccs+/+ 
mice. Postnatal normalization of heart weight and cardiac output compared to vehicle 
treated mice is similar in both genotypes. Thus, any effect of prenatal mTORC1 inhibition 
specifically in cHccs+/- hearts can be compensated until early adulthood under baseline 
conditions. It would be interesting, however, to evaluate whether this still holds true if the 
heart is challenged by pressure overload, neurohumoral stimulation or ischemia. 
Furthermore, after prenatal rapamycin treatment mTORC1 activity is restored at postnatal 
day3. Our previous study has shown normalization of heart size by compensatory 
cardiomyocyte hypertrophy in cHccs+/- mice by the age of 10 weeks, whereas hearts were 
still considerable smaller at postnatal day 
10.12 Th s, postnatal compen atory growth ex ends well beyond P3, such th t the precise 
role f mTORC1 in this process cannot be assessed by the curr nt study but would require 






























































































































































Table S1. Echocardiographic measurements in neonatal mice after prenatal mTORC1 inhibition 
Echocardiography was performed on postnatal day 1 in Hccs+/+ and cHccs+/- mice after prenatal rapamycin or vehicle treatment. Left ventricular 
(LV) wall thickness and diameter were determined in end-diastole (dia) and end-systole (sys) and LV mass, contractility and output were calculated
(§p<0.05 vs. vehicle Hccs+/+, §§p<0.01 vs. vehicle Hccs+/+, #p<0.05 vs. vehicle cHccs+/-). (EF: ejection fraction, FS: fractional shortening,





























































































































































Table S2. Body and organ weights in adult mice after prenatal rapamycin or vehicle treatment. 
Body and organ weights were determined in 11 week old Hccs+/+ and cHccs+/- mice after prenatal rapamycin or vehicle treatment (§p<0.05 vs. 
vehicle Hccs+/+, §§p<0.01 vs. vehicle Hccs+/+, #p<0.05 vs. vehicle cHccs+/-). (BW: body weight, KW: kidney weight, LW: liver weight, SW: spleen 





























































































































































































Table S3. Echocardiographic measurements in adult mice after prenatal mTORC1 inhibition. 
Echocardiography was performed in 11 week old Hccs+/+ and cHccs+/- mice after prenatal rapamycin or vehicle treatment. Left ventricular (LV) wall 
thickness and diameter were determined in end-diastole (dia) and end-systole (sys) and LV mass, contractility and output were calculated. (EF: 
ejection fraction, FS: fractional shortening, IVS: interventricular septum, LVID: left ventricular internal diameter, LVPW: left ventricular posterior 






Figure S1. Inhibition of mTORC1 in fetal and neonatal mice by rapamycin treatment of 
pregnant dams. Rapamycin was injected subcutaneously at a dose of 5 mg per kg body 
weight in pregnant dams every 12 h from 15.5 dpc until delivery. As controls, pregnant dams 
were injected with vehicle only. 
 
 
Figure S2. Evaluation of the autophagy regulating kinases AMPK and ULK1 in neonatal 
hearts after prenatal rapamycin treatment. (A) Phosphorylation of the AMPK (AMP-activated 
protein kinase) subunit α is increased in neonatal hearts after prenatal rapamycin treatment, 
indicating AMPK activation. (B) The kinase ULK1 (Unc-51 like autophagy activating kinase 1) 
is phosphorylated by AMPK at Ser555 to initiate autophagy whereas mTOR phosphorylates 
ULK1 at Ser757 to inhibit autophagy. Consistent with AMPK activation ULK1 Ser555 
phosphorylation is increased in neonatal hearts after prenatal rapamycin treatment, whereas 
Ser757 phosphorylation is unchanged when normalized to total ULK1. Note that the latter is 
confounded by a significant increase in total ULK1 protein levels in rapamycin compared to 




Figure S3. Unaltered phosphorylation of mTOR, ULK1, 4E-BP1 and Akt in neonatal cHccs+/- 
hearts. (A) Phosphorylation of mTOR at Ser2448 and Ser2481 is unaltered in neonatal 
cHccs+/- hearts compared to controls. Similarly, no difference in total protein amounts of 
mTOR or its interacting proteins RAPTOR or RICTOR (specific for mTOR complex 1 and 2, 
respectively) is detected between groups (densitometric quantification n=8 per genotype; POI 
= protein of interest). (B) Phosphorylation of the mTORC1 downstream targets 4E-BP1 and 
ULK1 (at the mTORC1 dependent site Ser757) is not different between neonatal cHccs+/- and 
control hearts. The kinase Akt acts as both an upstream regulator of mTORC1 as well as 
mTORC2 downstream target. Phosphorylation of Akt at Thr308 (via the PI3K pathway) and 






Figure S4. Prenatal mTORC1 inhibition in cHccs+/- fetuses does not cause lethality prior to 
birth. (A) Western blots of heart protein extracts from neonatal (P1) cHccs+/- females and 
their Hccs+/+ female littermate controls after prenatal vehicle or rapamycin treatment 
illustrating phosphorylation status of the mTORC1 downstream targets S6K1, S6 and 4E-
BP1. Note increased mTORC1 activity towards S6K1 and S6 in cHccs+/- females in vehicle 
treated animals (see main text and Figure 4) but similar reduction of S6K1 and S6 
phosphorylation in hearts of rapamycin compared to vehicle treated offspring, indicating 
successful mTORC1 inhibition in cHccs+/- hearts. Phosphorylation of 4E-BP1 was 
demonstrated to be unaffected by prenatal rapamycin treatment (see main text and Figure 
1). (B) Genotype distribution within vehicle as well as rapamycin treated litters was not 
significantly different from expected genotype frequencies, indicating that cHccs+/- females do 
not exhibit prenatal lethality due to mTORC1 inhibition. Statistical significance between 
treatment groups and the expected genotype distribution was assessed by chi-square test. 
Statistical significance comparing the frequencies of each genotype between vehicle and 
rapamycin treated litters was assessed by unpaired 2-tailed Student t-tests (n=9 litters per 
group). 
 Figure S5. No preferential death of rapamycin treated cHccs+/- females after birth. (A) 
Breeding of males hemizygous for the “floxed” Hccs allele (Hccsfloxed/y/Nkx2.5+/+) to females 
homozygous for the Nkx2.5Cre allele (Hccs+/+/Nkx2.5Cre/Cre) generates two possible offspring 
genotypes, i.e. control males (Hccs+/y/Nkx2.5Cre/+) and heterozygous heart conditional Hccs 
knockout females (Hccsfloxed/+/Nkx2.5Cre/+) at an expected ratio of 50:50. (B) Breeding of 
males homozygous for the Nkx2.5Cre allele (Hccs+/y/Nkx2.5Cre/Cre) to females heterozygous 
for the “floxed” Hccs allele (Hccsfloxed/+/Nkx2.5+/+) generates three postnatally viable 
genotypes, i.e. control males (Hccs+/y/Nkx2.5Cre/+), control females (Hccs+/+/Nkx2.5Cre/+) and 
heterozygous heart conditional Hccs knockout females (Hccsfloxed/+/Nkx2.5Cre/+) at an 
expected ratio of 33% each. Hemizygous heart conditional Hccs knockout males 
(Hccsfloxed/y/Nkx2.5Cre/+) die in utero at stage 10.5 dpc.11 Genotype distribution within vehicle 
as well as rapamycin treated litters was evaluated at weaning (i.e. at 21 days of age). For 
both breeding schemes no significant difference compared to expected genotype frequencies 
was observed, indicating that rapamycin treated cHccs+/- females do not preferentially die 
within the first 12 days after birth (see Figure 6A). Statistical significance between treatment 
groups and the expected genotype distribution was assessed by chi-square test (3 litters per 




Figure S6. Prenatal mTORC1 inhibition does not cause significantly different tissue 
remodeling in adult cHccs+/- compared to Hccs+/+ hearts. (A) Fluorescence images of cross-
sectioned cardiomyocytes within the left ventricular (LV) myocardium of adult hearts. 
Cardiomyocyte membranes were stained in red with wheat germ agglutinin (WGA) and 
nuclei in blue with DAPI (scale bar = 100 μm). Cardiomyocyte cross sectional area (CSA) 
was significantly larger in Hccs+/+ as well as cHccs+/- hearts exposed to prenatal rapamycin 
compared to vehicle treatment. Note that compensatory cardiomyocyte hypertrophy in 
cHccs+/- mice reported previously 12 is evident in the vehicle group but lost in rapamycin 
treated hearts (vehicle Hccs+/+ n=6, rapamycin Hccs+/+ n=7, vehicle and rapamycin cHccs+/- 
n=5). (B) Representative images of Sirius Red stained LV myocardium of adult mice. White 
arrowheads highlight interstitial fibrosis whereas black arrowheads indicate perivascular 
fibrosis, which was excluded from quantification (scale bar = 300 μm). The contribution of 
fibrotic tissue to the LV myocardium of adult mice did not reveal differences between 
treatment groups or genotypes (n=6 for all groups, except vehicle cHccs+/- n=8). (C) Relative 
Nppa, Myh7 and Nppb RNA expression in adult hearts was determined using qRT-PCR to 
evaluate pathological conditions. No major changes in gene expression were observed in 
rapamycin (R) compared to vehicle (V) groups in either Hccs+/+ or cHccs+/- hearts (n=8 per 
group). Note that data used for Hccs+/+ animals in (A) – (C) are the same as depicted in 
Figure 8. (*p<0.05, **p<0.01, §§p<0.01 vs. vehicle Hccs+/+, #p<0.05 vs. vehicle cHccs+/-). 
  
Supplemental References: 
1. Drenckhahn JD, Schwarz QP, Gray S, Laskowski A, Kiriazis H, Ming Z, Harvey RP, Du XJ,
Thorburn DR, Cox TC. Compensatory growth of healthy cardiac cells in the presence of diseased
cells restores tissue homeostasis during heart development. Dev Cell. 2008;15:521-533.
2. Drenckhahn JD, Strasen J, Heinecke K, Langner P, Yin KV, Skole F, Hennig M, Spallek B,
Fischer R, Blaschke F, Heuser A, Cox TC, Black MJ, Thierfelder L. Impaired myocardial
development resulting in neonatal cardiac hypoplasia alters postnatal growth and stress response
in the heart. Cardiovasc Res. 2015;106:43-54.
3. Foglia MJ, Poss KD. Building and re-building the heart by cardiomyocyte proliferation.
Development. 2016;143:729-740.
Maria Hennig, Saskia Fiedler, Christian Jux, Ludwig Thierfelder and Jörg-Detlef Drenckhahn
Cardiac Growth, Morphology, and Function
Treatment of Pregnant Mice Causes Intrauterine Growth Restriction and Alters Postnatal 
Prenatal Mechanistic Target of Rapamycin Complex 1 (m TORC1) Inhibition by Rapamycin
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.117.005506
2017;6:e005506; originally published August 4, 2017;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/6/8/e005506
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
